SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

Share Price is delayed by 15 minutes
Get Live Data
2.21    0.00 (0.00%)
Bid:
2.19
Ask:
2.21
Spread: 0.02 (0.913%)
Market Cap: $714.60m
RTW Live PriceLast checked at - London Stock Exchange

Intraday Rtw Biotech Share Chart

Monthly Valuation Update and Factsheet

14 Feb 2025 07:00

RNS Number : 0864X
RTW Biotech Opportunities Ltd
14 February 2025
 

LEI: 549300Q7EXQQH6KF7Z84

14 February 2025

RTW Biotech Opportunities Ltd

Monthly Valuation Update and Factsheet

+4.3% NAV movement for the month

RTW Biotech Opportunities Ltd (the "Company") announces that the unaudited net asset value attributable to the ordinary shares of the Company at the close of business on 31 January 2025 (the "NAV") was US$632.8 million, or US$1.89 per ordinary share, +4.3% from the previous month.

The monthly factsheet is available on the Company's website:

 

https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/factsheets-letters/

 

 

For Further Information

RTW Investments, LP

+44 20 7959 6361

Woody Stileman, Managing Director, Business Development

Krisha McCune, Director, Investor Relations

biotechopportunities@rtwfunds.com

 

Cadarn Capital (PR & Communications / Distribution & IR Partner)

Lucy Clark (PR)

David Harris (Distribution)

 

 

Deutsche Numis (Joint Corporate Broker)

 

+44 79 8418 4461

Lucy@cadarncapital.com

+44 73 6888 3211

david@cadarncapital.com

 

+44 20 7260 1000

Freddie Barnfield

 

Nathan Brown

 

Euan Brown

 

 

BofA Securities (Joint Corporate Broker)

+44 20 7628 1000

Edward Peel

 

Alex Penney

 

 

Altum (Guernsey) Limited (previously named Elysium Fund Management Limited)

 

+44 14 8170 3100

 

Joanna Duquemin Nicolle, Director

 

 

Sadie Morrison, Director

 

 

Morgan Stanley Fund Services USA LLC

+1 914 225 8885

 

About Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.

***********

The information in this announcement may include forward-looking statements, which are based on the current expectations and projections about future events, and in certain cases can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue", "target", "believe" (or the negatives thereon) or other variations thereon or comparable terminology. These forward-looking statements, as well as those included in any related materials, are subject to risks, uncertainties and assumptions about the Company and/or its underlying investments, including, among other things, the development of the applicable entity's business, trends in its operating industry, expected use of financing proceeds and future capital expenditures and acquisitions. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur.

The information contained in this announcement is given at the date of its publication (unless otherwise marked). No reliance may be placed for any purpose whatsoever on the information or opinions contained in this announcement or on its completeness, accuracy or fairness.

***********

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DOCDXLFFELLEBBK
Date   Source Headline
27th Sep 20247:00 amRNSBioAge Labs completes $198 million IPO
26th Sep 20247:00 amRNSGBP quote for the share class to cease
16th Sep 20247:00 amRNSMonthly Valuation Update and Factsheet
13th Sep 20247:00 amRNSHalf-year Report
14th Aug 20247:01 amRNSClosed Period Notification
14th Aug 20247:00 amRNSMonthly Valuation Update and Factsheet
6th Aug 20247:00 amRNSNew Investment in Jade Biosciences, Inc
22nd Jul 202412:00 pmRNSArtiva Biotherapeutics prices IPO at $167 million
15th Jul 20247:00 amRNSMonthly Valuation Update and Factsheet
11th Jul 20247:00 amRNSBaroness Blackwood Appointed as Independent NED
2nd Jul 20247:00 amRNSInvestment in Mirador Therapeutics & Santa Ana Bio
1st Jul 20247:00 amRNSTotal Voting Rights
14th Jun 20247:00 amRNSMonthly Valuation Update and Factsheet
13th Jun 20247:00 amRNSPositive Data Announcement - Avidity Biosciences
11th Jun 20247:00 amRNSPortfolio Company Numab Therapeutics Update
5th Jun 20247:00 amRNSTransaction in Own Shares
3rd Jun 20247:00 amRNSTotal Voting Rights
31st May 202412:00 pmRNSDirector Declaration
31st May 20247:00 amRNSTransaction in Own Shares
29th May 20247:00 amRNSHolding(s) in Company
28th May 20247:00 amRNSHolding(s) in Company
24th May 202412:00 pmRNSCancellation of Own Shares
16th May 20244:47 pmRNSResult of AGM
15th May 20247:01 amRNSTransaction in Own Shares
15th May 20247:00 amRNSAdditional Investment in Lycia Therapeutics
14th May 20247:00 amRNSMonthly Valuation Update and Factsheet
1st May 20247:01 amRNSTotal Voting Rights
1st May 20247:00 amRNSTransaction in Own Shares
26th Apr 20247:00 amRNSTransaction in Own Shares
25th Apr 20244:46 pmRNSAnnual Financial Report
24th Apr 20247:00 amRNSTransaction in Own Shares
19th Apr 20247:00 amRNSTransaction in Own Shares
18th Apr 20249:30 amRNSNotice of AGM
16th Apr 20247:00 amRNSTransaction in Own Shares
15th Apr 20247:00 amRNSMonthly Valuation Update and First Quarter Letter
12th Apr 20245:42 pmRNSPortfolio Company Update: Artios Pharma
12th Apr 20247:00 amRNSTransaction in Own Shares
9th Apr 20247:00 amRNSTransaction in Own Shares
8th Apr 20247:00 amRNSTransaction in Own Shares
5th Apr 202410:00 amRNSNew Investment: Obsidian Therapeutics
5th Apr 20247:01 amRNSTransaction in Own Shares
4th Apr 20247:00 amRNSTransaction in Own Shares
2nd Apr 20247:01 amRNSTotal Voting Rights
2nd Apr 20247:00 amRNSTransaction in Own Shares
28th Mar 20247:01 amRNSTransaction in Own Shares
28th Mar 20247:00 amRNSAnnual Financial Report
27th Mar 20247:00 amRNSTransaction in Own Shares
22nd Mar 20247:00 amRNSTransaction in Own Shares
19th Mar 20247:00 amRNSTransaction in Own Shares
15th Mar 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.